

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

Claims 1-8. (canceled)

Claim 9 (original) In an implant adapted for subcutaneous implantation in an animal's ear by an implanter apparatus through the bore of a hypodermic needle which is coupled to a pellet magazine, the improvement comprising:

- (a) said implant including a plurality of pellets sized and shaped to be implanted through the needle and positioned in the magazine for selective alignment of the implant with the needle; and
- (b) the pellets of a single implant including both at least one immediate release parasitocidal agent pellet dose and at least one extended release parasitocidal agent pellet dose.

Claim 10 (original) The implant according to Claim 9 wherein the pellets are packaged in the magazine in sequential order for delivery of an immediate release parasitocidal agent dose in at least one discrete pellet followed by an extended release parasitocidal agent dose in at least one pellet for subcutaneous placement in a single injection.

Claim 11 (currently amended) The implant according to Claim 10 wherein said immediate release and said extended release parasitocidal agent pellet doses separately comprise a parasitocidal agent selected from the group consisting of avermectins, milbemycins, milbemycin oximes, fenbendazoles, lufenexons, derivatives and mixtures thereof.

Claim 12 (original) The implant according to Claim 11 wherein said parasitocidal agent comprises an avermectin selected from the group consisting of ivermectin, doramectin, moxidectin, eprinomectrin, abamectin, derivatives and mixtures thereof.

Claim 13 (original) The implant according to Claim 10 wherein said immediate release parasitocidal agent pellet dose further comprises a disintegration agent and said extended release parasitocidal agent pellet dose further comprises a bioerodible matrix.

Claim 14 (original) An implant for subcutaneous implantation in an animal's ear comprising:

- (a) at least one discrete immediate release parasitocidal agent pellet dose;
and
- (b) at least one discrete extended release parasitocidal agent pellet dose,
said pellet dose being combined in a single unit and being injectable into
an animal at the same time for implantation side by side into the same
site.

Claim 15 (original) The implant according to Claim 14 further comprising an excipient and wherein each of said immediate release and said extended release parasitocidal agent pellet doses separately comprise a parasitocidal agent selected from the group consisting of the avermectins, milbemycins, milbemycin oximes, fenbendazoles, lufernerons, derivatives and mixtures thereof.

Claim 16 (currently amended) The implant according to Claim 15 wherein said parasitocidal agent comprises an avermectin selected from the group consisting of ivermectin, doramectin, moxidectin, eprinomectin, abamectin, derivatives and mixtures thereof.

Claim 17 (original) The implant according to Claim 14 wherein each immediate release parasitocidal agent pellet dose further comprises a disintegration agent and each extended release parasitocidal agent pellet dose further comprises a bioerodable matrix.

Claim 18 (original) An implant adapted for subcutaneous implantation in an animal's ear comprising:

an immediate release pharmaceutical composition comprising at least
one parasitocidal agent and a disintegration aid; and
an extended release pharmaceutical composition comprising at least one
parasitocidal agent and a binding agent.

Claim 19 (original) The implant of Claim 18, said parasitocidal agent being selected from the group consisting of avermectins, milbemycins, milbemycin oximes, fenbendazoles, lufenexons, derivatives and mixtures thereof.

Claim 20 (original) The implant of Claim 19, said parasitocidal agent comprising an avermectin selected from the group consisting of ivermectin, doramectin, moxidectin, eprinomectin, abamectin, derivatives and mixtures thereof.

Claim 21 (original) The implant of Claim 18, said immediate release pharmaceutical composition comprising from about 25-125 mg of said parasitocidal agent.

Claim 22 (original) The implant of Claim 18, said extended release pharmaceutical composition comprising from about 50-175 mg of said parasitocidal agent.

Claim 23 (original) The implant of Claim 18, said disintegration aid being selected from the group consisting of magnesium stearate, croscarmellose sodium, microcrystalline cellulose, derivatives and mixtures thereof.

Claim 24 (original) The implant of Claim 18, said binding agent being selected from the group consisting of lactose, polyethylene glycol, magnesium stearate, cellulose, ethylcellulose, polymeric supports, binders, coloring agents, derivatives and mixtures thereof.

Claim 25 (original) The implant of Claim 18, said extended release pharmaceutical composition having a delivery period of at least 120 days.

Claim 26 (original) A method for providing immediate and extended control of parasite infestation in an animal comprising the steps of:

- (a) providing an implant adapted for subcutaneous implantation in an animal's ear comprising an immediate release pharmaceutical composition comprising at least one parasitocidal agent and a disintegration aid, and an extended release pharmaceutical composition comprising at least one parasitocidal agent and a binding agent; and
- (b) implanting said implant into an animal's ear.

Claim 27 (original) The method of Claim 26, said parasitocidal agent being selected from the group consisting of avermectins, milbemycins, milbemycin oximes, fenbendazoles, lufenexons, derivatives and mixtures thereof.

Claim 28 (original) The method of Claim 27, said parasitocidal agent comprising an avermectin selected from the group consisting of ivermectin, doramectin, moxidectin, eprinomectin, abamectin, derivatives and mixtures thereof.

Claim 29 (original) The method of Claim 26, said immediate release pharmaceutical composition comprising from about 25-125 mg of said parasitocidal agent.

Claim 30 (original) The method of Claim 26, said extended release pharmaceutical composition comprising from about 50-175 mg of parasitocidal agent.

Claim 31 (original) The method of Claim 26, said disintegration aid being selected from the group consisting of magnesium stearate, croscarmellose sodium, microcrystalline cellulose, derivatives and mixtures thereof.

Claim 32 (original) The method of Claim 26, said binding agent being selected from the group consisting of lactose, polyethylene glycol, magnesium stearate, cellulose, ethylcellulose, polymeric supports, binders, coloring agents, derivatives and mixtures thereof.

Claim 33 (original) The method of Claim 26, said extended release pharmaceutical composition having a delivery period of at least 120 days.